Genprex Inc (NASDAQ:GNPX) has appointed two experienced life sciences executives as the firm advances its lead drug candidate into key clinical programs and pursues partnerships for its cancer platform and newly licensed gene therapy technology for diabetes.
Catherine M Vaczy becomes executive vice president and chief strategy officer, while Michael T Redman becomes executive vice president and chief operating officer.
These appointments follow hot on the heels of Genprex receiving fast track designation from the FDA for its lead drug candidate Oncoprex for non-small cell lung cancer, its newly licensed gene therapy for diabetes and a capital raise of over $26 million to support funding its clinical programs.
Rodney Varner, Genprex CEO, said: "Their combined expertise in business development, corporate strategy, manufacturing, clinical trial strategy and operations and regulatory affairs will be of great value as we build Genprex into a leading gene therapy company bringing new treatment options to patients in need."
"We are fortunate to have raised over $26 million just prior to the current turmoil in the markets, significantly strengthening our balance sheet and well positioning us financially as we execute on our strategic plan," he added.
Ms Vaczy has over 20 years' experience as a founder and senior executive of life science companies. Her CV includes experiences with NeoStem Inc (now Caladrius Biosciences), a Nasdaq-listed clinical stage biotechnology company and ImClone Systems Incorporated (sold to Eli Lily and Company).
Meanwhile, Redman brings more than 30 years of experience in the life sciences industry. He has held a variety of key executive roles at clinical-stage companies, where he focused on strategic business development and US and worldwide manufacturing and clinical operations, the firm said.
Redman was president, CEO and director of Oncolix Inc, a publicly traded clinical-stage biopharma focused on developing therapies for women’s and children’s cancers.
In 2001, he co-founded Opexa Pharmaceuticals, a company developing immunotherapies for a variety of diseases, and served as its president and CEO until 2005. He has worked at Zonagen (now Repros Therapeutics, which is a part of Allergan), Aronex Pharmaceuticals, Biovail Corporation and American Home Products (acquired by Pfizer).
Contact the author at [email protected]